STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNDA
  4. [8-K] Vanda Pharmaceuticals Inc. Reports Material Event

Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vanda Pharmaceuticals Inc. reported that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary. He notified the company on March 29, 2026, and his resignation will be effective April 10, 2026, as he plans to pursue other endeavors.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Notification date March 29, 2026 Date Timothy Williams notified Vanda of his resignation
Effective resignation date April 10, 2026 Date Timothy Williams’ resignation becomes effective
Filing date April 2, 2026 Date Vanda Pharmaceuticals submitted the Form 8-K
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Senior Vice President, General Counsel and Secretary financial
"his resignation as the Company’s Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026"
Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
0001347178FALSE00013471782026-03-292026-03-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2026 (March 29, 2026)
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
Delaware001-3418603-0491827
(State or other jurisdiction of incorporation)(Commission File No.)(IRS Employer Identification No.)
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (202) 734-3400
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareVNDAThe Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨


Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Resignation of Executive Officer
On March 29, 2026, Timothy Williams notified Vanda Pharmaceuticals Inc. (the “Company”) of his resignation as the Company’s Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026, in order to pursue other endeavors.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:April 2, 2026 VANDA PHARMACEUTICALS INC.
 By:/s/ Kevin Moran
 Name:Kevin Moran
 Title:Senior Vice President, Chief Financial Officer and Treasurer

Source: View Original Filing on SEC EDGAR

FAQ

What did Vanda Pharmaceuticals (VNDA) announce in this 8-K filing?

Vanda Pharmaceuticals announced the resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary. He informed the company on March 29, 2026, and his departure will be effective April 10, 2026, as he intends to pursue other endeavors.

Who is resigning from Vanda Pharmaceuticals (VNDA) and what was his role?

Timothy Williams is resigning from Vanda Pharmaceuticals. He served as Senior Vice President, General Counsel and Secretary, overseeing the company’s top legal and corporate secretary functions as a key member of the senior executive team.

When will the resignation of Vanda Pharmaceuticals’ General Counsel take effect?

The resignation of Vanda Pharmaceuticals’ Senior Vice President, General Counsel and Secretary, Timothy Williams, will take effect on April 10, 2026. He notified the company of his decision on March 29, 2026, providing advance notice of his planned departure.

Why is Vanda Pharmaceuticals’ General Counsel Timothy Williams resigning?

Timothy Williams is resigning from his role as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals in order to pursue other endeavors. The filing states this reason without providing further detail about his future plans or destinations.

Does the Vanda Pharmaceuticals 8-K mention any replacement for the General Counsel?

The 8-K filing notes only that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary effective April 10, 2026. It does not identify or describe any successor or interim appointment in the disclosed text.

Filing Exhibits & Attachments

3 documents

Other Documents